The New Diabetic Drug Can Help Obese With Weight Loss

According to new findings from the SURMOUNT–1 trial, once-weekly doses of 5, 10 and 15 mg of tirzepatide can significantly reduce body weight among obese individuals.

The 19.5 and 20.9% weight reduction was observed with 10 and 15 mg doses of tirzepatide, respectively in the participants.

Ania M. Jastreboff a key author of the study said, “This is an unusually substantial degree of weight reduction in response to an anti-obesity medication as compared with findings reported in another phase 3 clinical trials.” She believes that, because tirzepatide is both a GIP receptor and GLP-1 receptor agonist, and speculates that there may be an additive benefit in targeting multiple endogenous nutrient-stimulated hormone pathways that have been implicated in energy homeostasis.” The team researchers noticed that beyond helping patients lose weight, tirzepatide treatment reduced systolic and diastolic blood pressure, fasting insulin levels, and lipid levels. Active treatment also led to higher physical function scores on SF-36.

According to Jastreboff, Tirzepatide has been observed to cause weight reduction at all three doses, making it a valuable medical tool for treating obesity. These findings were presented at the American Diabetes Association (ADA) 2022 Scientific Sessions.